智通财经APP讯，苑东生物(688513.SH)发布2025年半年度报告，该公司营业收入为6.54亿元，同比减少 2.25%。归属于上市公司股东的净利润为1.37亿元，同比减少6.77%。归属于上市公司股东的扣除非经常 性损益的净利润为1.04亿元，同比减少8.68%。基本每股收益为0.77元。营业收入及净利润较上年同期 下降，主要系执行第十批国家集中带量采购导致化学制剂销售收入下降及报告期内股权激励费用同比增 加所致。 ...

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has signed an agreement with an affiliated party to procure a production information system, aiming to enhance digital and intelligent management in the pharmaceutical industry [1][3]. Summary by Sections 1. Overview of the Related Transaction - The company’s wholly-owned subsidiary, Chengdu Shod Pharmaceutical Co., Ltd., plans to purchase a production information system from Beijing Qilijia Technology Co., Ltd. for a total amount of 2.2 million RMB, with a contract duration of three years [1][3][7]. 2. Basic Information of the Related Party - Beijing Qilijia Technology Co., Ltd. has a registered capital of 5 million RMB and was established on October 25, 2002. The company specializes in software development, technology consulting, and related services [2][5]. 3. Financial Data of the Related Party - As of June 30, 2025, Qilijia reported total assets of 1470.98 million RMB and total liabilities of 205.94 million RMB, with an owner's equity of 1265.04 million RMB. The company had a revenue of 392.14 million RMB in the first half of 2025 [5]. 4. Necessity and Impact of the Related Transaction - The transaction is essential for the company to implement digital and intelligent management in pharmaceutical production, aligning with the interests of the company and all shareholders. The pricing of the transaction is fair and does not harm the interests of minority shareholders [9][11]. 5. Approval Process for the Related Transaction - The independent directors and the board of supervisors have approved the transaction, confirming that it complies with the company's procurement management system and is based on fair market conditions [10][11].

经全体与会独立董事审议：本次关联交易是基于公司实施生产数字化智能管 理的实际业务而产生，主要目的是为了加快推进数字化、智能化在制药产业中融 合，实现药品生产数字化智能管理，符合公司和全体股东的利益，具有必要性。 本次交易严格按照公司采购管理制度及采购招标流程遴选供应商，按照公平、公 开、公正的原则从服务能力、解决方案、项目实施经验、项目团队能力等方面进 行综合全面考察，通过招投标流程比价，在符合商业惯例的前提下，从交易价格 谈判、付款方式及验收标准等方面保证上市公司利益，不会损害公司及股东特别 是中小股东的利益。我们同意将该关联交易事项提交公司第四届董事会第七次会 议审议，届时关联董事将回避表决。 表决结果：3 票同意、0 票反对、0 票弃权。 独立董事：李卫锋、程增江、方芳 成都苑东生物制药股份有限公司 第四届独立董事专门会议第三次会议决议 成都苑东生物制药股份有限公司（以下称"公司"）第四届独立董事专门会议 第三次会议通知于 2025 年 8 月 7 日以电话/微信等方式临时向全体独立董事发出， 会议于 2025 年 8 月 8 日以通讯表决方式召开。本次会议应出席独立董事 3 名， 实际出席独立董事 3 ...

Core Viewpoint - The company has decided to extend the investment timeline for certain fundraising projects, specifically the "Drug Clinical Research Project," to align with actual progress and strategic goals, without altering the project's content or financial commitments [3][6][8]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement is in place with the sponsor and the bank [1]. Investment Project Details - The company has made adjustments to its fundraising project allocations, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary [2]. - The total investment for the new project is RMB 10,905 million, with RMB 6,100 million sourced from the adjusted funds [2]. Project Timeline Adjustments - The investment period for the "Drug Clinical Research Project" has been extended by two years, now set to conclude on August 31, 2027 [6][8]. - The project includes two sub-projects: the "Vildagliptin Tablets" and "Morphine Sulfate and Naloxone Controlled-Release Capsules," with the former having completed Phase III trials [6]. Reasons for Delay - The delay is attributed to the need for additional clinical trials for the "Vildagliptin Tablets" to meet submission requirements for market approval, considering competitive market conditions and commercialization risks [6][8]. Impact of Delay - The project delay is deemed a prudent decision that will not adversely affect the company's normal operations or alter the investment's total amount, purpose, or scale [8][9]. Approval Process - The board and supervisory committee have approved the project delays, confirming that no shareholder meeting is required for this decision [8][9]. - Both the board and supervisory committee emphasize that the delay is in the best interest of shareholders and aligns with the company's long-term sustainable development [9]. Sponsor's Review - The sponsor has reviewed the project delay and found that all necessary approval procedures have been followed, with no changes to the project's financial commitments or objectives [9].

Core Viewpoint - Yuan Dong Bio (688513.SH) reported a decline in both revenue and net profit for the first half of 2025, primarily due to the implementation of the tenth batch of national centralized procurement and increased stock incentive expenses [1] Financial Performance - The company achieved operating revenue of 654 million yuan, a year-on-year decrease of 2.25% [1] - Net profit attributable to shareholders was 137 million yuan, down 6.77% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 104 million yuan, reflecting an 8.68% year-on-year decline [1] - Basic earnings per share stood at 0.77 yuan [1]

人民财讯8月18日电，苑东生物(688513)8月18日晚间披露2025年半年报，公司上半年实现营业收入6.54 亿元，同比下降2.25%；归母净利润1.37亿元，同比下降6.77%。基本每股收益0.77元。报告期内，营业 收入及净利润较上年同期下降，主要系执行第十批国家集中带量采购导致化学制剂销售收入下降及报告 期内股权激励费用同比增加所致。 ...

Core Viewpoint - Chengdu Easton Biopharmaceuticals Co., Ltd. reported a decrease in revenue and net profit for the first half of 2025, primarily due to the impact of national centralized procurement policies and increased equity incentive expenses, while maintaining a strong focus on innovation and product development in the pharmaceutical industry. Financial Performance - The company achieved operating revenue of CNY 654.45 million, a decrease of 2.25% compared to the same period last year [3] - Total profit amounted to CNY 149.74 million, down 6.10% year-on-year [3] - Net profit attributable to shareholders was CNY 136.57 million, a decline of 6.77% compared to the previous year [3] - The net cash flow from operating activities increased significantly by 83.16% to CNY 157.47 million [3] - The company's net assets reached CNY 2.78 billion, reflecting a growth of 3.05% from the end of the previous year [3] Business Overview - The company operates as a high-tech enterprise focusing on the research, development, production, and sales of chemical raw materials, high-end chemical drugs, and biological drugs [5] - It has successfully industrialized 66 high-end chemical drugs, including 8 domestic first-generic products and 57 that have passed consistency evaluations [5][14] - The company is actively engaged in the development of over 10 first-class new drugs and has a robust pipeline in the anesthetic and analgesic fields [5][14] Industry Context - The pharmaceutical manufacturing industry in China is transitioning from rapid growth to high-quality development, emphasizing the need for innovation and improved product quality [10][19] - The industry faces challenges such as low concentration, insufficient original innovation capabilities, and strong international competition in high-value products [12] - The demand for generic drugs remains significant due to the aging population and the increasing prevalence of chronic diseases, while innovative drugs are essential for addressing unmet clinical needs [11][19] Innovation and R&D - The company has increased its R&D investment, with R&D expenses accounting for 20.25% of operating revenue, up from 18.27% in the previous year [3][15] - It focuses on developing high-barrier, high-technical-difficulty generic drugs while accelerating the transition from generics to innovative drugs [5][15] - The company is enhancing its capabilities in antibody technology and bioconjugation technology, targeting oncology, anesthetic analgesia, and immune diseases [7][15] Market Position - The company holds a leading market share in the anesthetic and analgesic sectors, with 18 products launched and over 20 in development [14] - It has established a competitive advantage through a diverse product pipeline and strong market presence in chronic disease treatment [14][19] - The company has received multiple honors and recognitions, including being named a national high-tech enterprise and receiving various awards for its innovation and R&D capabilities [16][19]

成都苑东生物制药股份有限公司2025 年半年度报告摘要 公司代码：688513 公司简称：苑东生物 成都苑东生物制药股份有限公司 成都苑东生物制药股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到 http://www.sse.com.cn 网站仔细阅读半年度报告全文。 公司已在本报告中详细阐述公司在生产经营过程中可能面临的各种风险及应对措施，敬请查 阅第三节"管理层讨论与分析"之"四、风险因素"。敬请投资者予以关注，注意投资风险。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 上海证券交易所科 A股 苑东生物 688513 不适用 创板 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书 证券事务代表 姓名 李淑云 张敏 电话 028-86106668 028-86106668 办公地址 成都市双流区安康路8号 成都市双流区安康路8号 电子信箱 ydsw@eastonpharma.cn y ...

Meeting Overview - The fourth board meeting of Chengdu Yuandong Biopharmaceutical Co., Ltd. was held on August 18, 2025, with all 9 directors present, ensuring compliance with relevant laws and regulations [1][2]. Resolutions Passed - The board approved the half-year report and its summary for 2025, with a unanimous vote of 9 in favor [2][3]. - The board also approved a special report on the management and actual use of raised funds for the first half of 2025, confirming compliance with legal requirements and proper decision-making procedures [2][3]. - A report on the mid-year evaluation of the "Quality Improvement and Efficiency Recovery Action Plan for 2025" was also approved unanimously [3]. - The board agreed to postpone certain fundraising investment projects, stating that the decision was made based on practical circumstances and would not adversely affect normal operations [3][4]. - An agreement related to the production information system with a related party was approved, emphasizing the necessity of digital and intelligent management in the pharmaceutical industry [4].

证券代码：688513 证券简称：苑东生物 公告编号：2025-058 成都苑东生物制药股份有限公司 二、 监事会会议审议情况 经审议，会议以投票表决的方式通过以下议案： （一）审议通过《关于 <公司 ensp="ensp" 年半年度报告及其摘要="年半年度报告及其摘要"> 的议 案》 监事会认为：公司 2025 年半年度报告及其摘要的编制和审议程序符合相关 法律法规及《公司章程》等内部规章制度的规定，其内容与格式符合中国证监会 和上海证券交易所的各项规定，公允地反映了公司 2025 年半年度的财务状况和 经营成果等事项。 第四届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 成都苑东生物制药股份有限公司（以下简称"公司"）第四届监事会第六次会 议于 2025 年 8 月 18 日在公司会议室以现场形式召开。会议通知已于 2025 年 8 月 8 日以电话通知、电子邮件等方式送达全体监事。本次会议应出席监事 3 名， 实际出席监事 3 名，本次会议由监事会主席罗雯婕女士主 ...